You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

November 24, 2014

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

Aspirin: When should it be used for prevention of cardiovascular events?

Physicians debated the benefits versus the risks of aspirin for cardiovascular events in an editorial published in JAMA online November 17. » Read more about this complex issue

ER opioid analgesic with abuse-deterrent properties approved by FDA

An extended-release (ER) opioid analgesic, hydrocodone bitartrate (Hysingla ER, Purdue Pharma) has been approved by FDA for the management of pain severe enough to require daily, 24-hour, long-term opioid treatment. Alternative treatment options must also have been found to be inadequate. » The development of opioids that are harder to abuse evolves

Continuing Education

MTM essentials for weight management

This month's CE activity is part of a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. From February 2014 through January 2015, pharmacists can earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to educate pharmacists about the prevalence, health consequences, and nonpharmacologic and pharmacologic treatment options for obesity, with a focus on the recommendations made in the 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exam and earn up to 2 CPE credits, click here to log in with the session code 14DT12-FKX42.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

$125-million priority review voucher drug sale sets benchmark

Pharmaceutical manufacturers got a better idea of the value of FDA's Priority Review Vouchers (PRVs) recently after Gilead Sciences paid $125 million in cash for Knight Therapeutics' Neglected Tropical Disease PRV. » Knight sells PRV to Gilead

 

RELATED ARTICLES

Heart risk raised in women regularly using NSAIDs

Cost, use of opioid dependence treatment are increasing, spurring need for care management programs

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group